Psychiatry & Psychotherapy Podcast

Ketamine Update with Brandon Kitay, M.D.

01.27.2022 - By David Puder, M.D.Play

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

Esketamine is the first non-monoaminergic based medication which is FDA approved and indicated for treatment refractory depression. A longer duration of undertreated depression is associated with poor longitudinal functional outcomes. Instead of cycling patients through monoaminergic antidepressant trials and cognitive behavioral therapy approaches, according to Dr. Kitay, providers should consider treatments like esketamine much sooner in the treatment course. Link to full blog Link to Resource Library. 

More episodes from Psychiatry & Psychotherapy Podcast